Efficacy, safety, and tolerability of gemcitabine and cisplatin in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma.
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2018
Price : $35 *
At a glance
- Drugs Veliparib (Primary) ; Cisplatin; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 16 Jan 2018 Results published in the Cancer
- 16 Jun 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.